Artemis Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.118 million compared to USD 0.003 million a year ago. Net loss was USD 0.444 million compared to USD 0.069 million a year ago. Basic loss per share from continuing operations was USD 0.01.
For the nine months, sales was USD 0.195 million compared to USD 0.007 million a year ago. Net loss was USD 0.849 million compared to USD 0.147 million a year ago. Basic loss per share from continuing operations was USD 0.02.